Investors

Press Releases

All Releases

View Summary Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on February 14, 2013
Jan 28, 2013
PDF 9.3 KB Add to Briefcase
View Summary Regeneron Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation
Jan 4, 2013
PDF 11.9 KB Add to Briefcase
View Summary Regeneron Announces January 2013 Investor Conference Presentations
Dec 20, 2012
PDF 9.7 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Submitted for EU Marketing Authorization for the Treatment of Macular Edema Following Central Retinal Vein Occlusion
Dec 6, 2012
PDF 18.9 KB Add to Briefcase
View Summary Regeneron Named Biotechnology Company of the Year
Nov 29, 2012
PDF 10.4 KB Add to Briefcase
View Summary Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
Nov 27, 2012
PDF 9.3 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Nov 27, 2012
PDF 18.7 KB Add to Briefcase
View Summary ZALTRAP® (ziv-aflibercept) Receives CHMP Positive Opinion in the European Union for Previously Treated Metastatic Colorectal Cancer
Nov 16, 2012
PDF 24.3 KB Add to Briefcase
View Summary Regeneron Announces November 2012 Investor Conference Presentations
Nov 6, 2012
PDF 9.7 KB Add to Briefcase
View Summary Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
Nov 5, 2012
PDF 21.6 KB Add to Briefcase
View Summary Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Oct 31, 2012
PDF 19.6 KB Add to Briefcase
View Summary Regeneron Reports Third Quarter 2012 Financial and Operating Results
Oct 24, 2012
PDF 30.9 KB Add to Briefcase
View Summary Regeneron Announces Publication of EYLEA® (aflibercept) Injection Phase 3 VIEW 1 and VIEW 2 Studies in Ophthalmology
Oct 18, 2012
PDF 18.3 KB Add to Briefcase
View Summary Regeneron to Report Third Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on October 24, 2012
Oct 10, 2012
PDF 9.5 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan
Sep 28, 2012
PDF 19.9 KB Add to Briefcase
View Summary Regeneron Announces FDA Approval of EYLEA® (aflibercept) Injection For Macular Edema Following Central Retinal Vein Occlusion
Sep 21, 2012
PDF 18.3 KB Add to Briefcase
View Summary Regeneron Named World's #1 Biopharmaceutical Employer in Science Magazine Annual Survey
Sep 21, 2012
PDF 10.8 KB Add to Briefcase
View Summary EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in Europe
Sep 21, 2012
PDF 18.5 KB Add to Briefcase
View Summary Regeneron Announces September 2012 Investor Conference Presentations
Aug 29, 2012
PDF 9.7 KB Add to Briefcase
View Summary U.S. FDA Approves ZALTRAP® (ziv-aflibercept) After Priority Review for Previously Treated Metastatic Colorectal Cancer
Aug 3, 2012
PDF 76.6 KB Add to Briefcase
Showing 101-120 of 258 Page: 1 2 3 4 5 6 7 8 9 10 ... 13  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase


Close
Form content here please :)